Bonato A, Raparelli G, Caruso M
Front Physiol. 2024; 15:1496870.
PMID: 39717824
PMC: 11663947.
DOI: 10.3389/fphys.2024.1496870.
Laurent M, Geoffroy M, Pavani G, Guiraud S
Cells. 2024; 13(10.
PMID: 38786024
PMC: 11119143.
DOI: 10.3390/cells13100800.
Szwec S, Kaplucha Z, Chamberlain J, Konieczny P
BioDrugs. 2023; 38(1):95-119.
PMID: 37917377
PMC: 10789850.
DOI: 10.1007/s40259-023-00632-3.
Roberts T, Wood M, Davies K
Nat Rev Drug Discov. 2023; 22(11):917-934.
PMID: 37652974
DOI: 10.1038/s41573-023-00775-6.
Gleneadie H, Fernandez-Ruiz B, Sardini A, Van de Pette M, Dimond A, Prinjha R
Commun Biol. 2023; 6(1):318.
PMID: 36966198
PMC: 10039851.
DOI: 10.1038/s42003-023-04666-9.
Postdevelopmental knockout of Orai1 improves muscle pathology in a mouse model of Duchenne muscular dystrophy.
Garcia-Castaneda M, Michelucci A, Zhao N, Malik S, Dirksen R
J Gen Physiol. 2022; 154(9).
PMID: 35939054
PMC: 9365874.
DOI: 10.1085/jgp.202213081.
Inactivation of Sirt6 ameliorates muscular dystrophy in mdx mice by releasing suppression of utrophin expression.
Georgieva A, Guo X, Bartkuhn M, Gunther S, Kunne C, Smolka C
Nat Commun. 2022; 13(1):4184.
PMID: 35859073
PMC: 9300598.
DOI: 10.1038/s41467-022-31798-z.
Therapeutic potential of highly functional codon-optimized microutrophin for muscle-specific expression.
Starikova A, Skopenkova V, Polikarpova A, Reshetov D, Vassilieva S, Velyaev O
Sci Rep. 2022; 12(1):848.
PMID: 35039573
PMC: 8764061.
DOI: 10.1038/s41598-022-04892-x.
Duchenne muscular dystrophy cell culture models created by CRISPR/Cas9 gene editing and their application in drug screening.
Soblechero-Martin P, Albiasu-Arteta E, Anton-Martinez A, de la Puente-Ovejero L, Garcia-Jimenez I, Gonzalez-Iglesias G
Sci Rep. 2021; 11(1):18188.
PMID: 34521928
PMC: 8440673.
DOI: 10.1038/s41598-021-97730-5.
Muscular dystrophy: Experimental animal models and therapeutic approaches (Review).
Gaina G, Popa Gruianu A
Exp Ther Med. 2021; 21(6):610.
PMID: 33936267
PMC: 8082581.
DOI: 10.3892/etm.2021.10042.
Targeting IRES-dependent translation as a novel approach for treating Duchenne muscular dystrophy.
Peladeau C, Jasmin B
RNA Biol. 2020; 18(9):1238-1251.
PMID: 33164678
PMC: 8354616.
DOI: 10.1080/15476286.2020.1847894.
The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy.
Guiraud S, Edwards B, Babbs A, Squire S, Berg A, Moir L
Hum Mol Genet. 2019; 28(13):2189-2200.
PMID: 30990876
PMC: 6586144.
DOI: 10.1093/hmg/ddz049.
Regenerative biomarkers for Duchenne muscular dystrophy.
Guiraud S, Davies K
Neural Regen Res. 2019; 14(8):1317-1320.
PMID: 30964048
PMC: 6524502.
DOI: 10.4103/1673-5374.253534.
Recent advances in Duchenne muscular dystrophy.
Perkins K, Davies K
Degener Neurol Neuromuscul Dis. 2019; 2:141-164.
PMID: 30890885
PMC: 6065571.
DOI: 10.2147/DNND.S26637.
Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy.
Lim K, Yoon C, Yokota T
J Pers Med. 2018; 8(4).
PMID: 30477208
PMC: 6313657.
DOI: 10.3390/jpm8040038.
Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD.
Guiraud S, Edwards B, Squire S, Moir L, Berg A, Babbs A
Hum Mol Genet. 2018; 28(2):307-319.
PMID: 30304405
PMC: 6322073.
DOI: 10.1093/hmg/ddy353.
Functional improvement of dystrophic muscle by repression of utrophin: let-7c interaction.
Mishra M, Loro E, Sengupta K, Wilton S, Khurana T
PLoS One. 2017; 12(10):e0182676.
PMID: 29045431
PMC: 5646768.
DOI: 10.1371/journal.pone.0182676.
High levels of sarcospan are well tolerated and act as a sarcolemmal stabilizer to address skeletal muscle and pulmonary dysfunction in DMD.
Gibbs E, Marshall J, Ma E, Nguyen T, Hong G, Lam J
Hum Mol Genet. 2016; 25(24):5395-5406.
PMID: 27798107
PMC: 5418831.
DOI: 10.1093/hmg/ddw356.
2015 William Allan Award.
Davies K
Am J Hum Genet. 2016; 98(3):419-426.
PMID: 26942278
PMC: 4800040.
DOI: 10.1016/j.ajhg.2016.01.007.
Advances in genetic therapeutic strategies for Duchenne muscular dystrophy.
Guiraud S, Chen H, Burns D, Davies K
Exp Physiol. 2015; 100(12):1458-67.
PMID: 26140505
PMC: 4973818.
DOI: 10.1113/EP085308.